CTOs on the Move

GoHealth Urgent Care

www.gohealthuc.com

 
GoHealth Urgent Care is one of the countrys fastest-growing and largest urgent care providers. At GoHealth Urgent Care, we place the needs of our patients first—by providing an effortless patient experience, a welcoming culture of care and seamless integration with market-leading health systems and our communities. GoHealth Urgent Care operates 80 urgent care centers in the New York and Portland, Oregon, metropolitan areas, the San Francisco Bay Area, Hartford, Connecticut, and will soon open urgent care centers in multiple Midwest markets. GoHealth Urgent Cares current partners include health systems that are at the forefront of care delivery innovation, including Northwell ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $50-100 Million
  • www.gohealthuc.com
  • 5555 Glenridge Connector Suite 700
    Atlanta, GA USA 30342
  • Phone: 678.774.7100

Executives

Name Title Contact Details
Andrew Neumann
 Chief Information Officer Profile
Dev Ashish
 Chief Information Officer Profile

Similar Companies

Glenn Long and Associates

Glenn Long and Associates, Inc. is a Hillsborough, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Axiom Fitness

Four premier health clubs in the Treasure Valley. Each facility features state of the art equipment, classes for all levels, friendly staff, professional fitness trainers, and flexible hours to help you reach your true potential through health and fit...

International Medical Equipment

International Medical Equipment is a San Marcos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SPARC

Cannabis dispensaries in San Francisco, Santa Rosa, and Sebastopol, SPARC offers same-day cannabis delivery in San Francisco and Sonoma County.

Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.